Kvantify, established in Copenhagen in January 2022, writes software that combines quantum computers with conventional supercomputers to simulate molecules for drug discovery. It was selected in the EIC Accelerator's January 2023 cut-off and received an EU grant of €2.50 million for KvasirAccelerator, a €4.50 million project that ran from August 2023 to July 2025, according to CORDIS. The goal was "the first utility-oriented, agnostic software platform for quantum-centric drug discovery".
The project is closed. Its final report states that Kvantify launched Koffee Unbinding Kinetics in March 2024 and Koffee Binding Affinity in October 2024, and planned to launch its quantum development kit in the fourth quarter of 2025, according to the CORDIS reporting page. That product arrived as Qrunch in November 2025. Kvantify's 2025 accounts show a net loss of DKK 36.1 million, a gross loss of DKK 20.0 million and negative equity of DKK 5.1 million, according to filings with the Danish Business Authority.
Company file
- Legal entity
- Kvantify ApS, CVR 42958093, Copenhagen
- Executive board
- Nikolaj Thomas Zinner, Allan Grønlund
- Executive chair
- Dr. Jörg Weiser
- Products
- Koffee Unbinding Kinetics, Koffee Binding Affinity, Qrunch
- Investors named
- EIC Fund, Delphinus Venture Capital
- Subsidiary
- Kvantify Ltd, London
- EIC funding
- Grant first; EIC Fund equity later
Where Kvantify Stands Now
In March 2026 Kvantify announced the second close of a €7 million funding round backed by the EIC Fund and Delphinus Venture Capital, according to its announcement. Its 2025 accounts record that the company took back 1,062,500 of its own shares for nothing under an agreement with "the former managing director and co-founder leaving the executive management", and that it agreed convertible debt financing at the start of 2026. Average staff fell from 49 to 37 in 2025.
"While conventional quantum software typically accesses only 10–30% of available qubits, Qrunch's chemistry-specific strategies enable efficient execution across entire processor architectures."
Nikolaj Zinner, chief scientific officer, Kvantify, November 2025The Technology: Chemistry Without Qubit Expertise
Qrunch hides the details of quantum hardware behind an interface built for chemists, so they can build quantum algorithms "without quantum expertise", the company said at its launch at the SC25 conference, according to PR Newswire; the final report describes "a generic interface for all quantum backends". The two Koffee products estimate how strongly drug candidates bind to their targets and how quickly they come off again. The final report names FAST-VQE, an algorithm the company developed for today's noisy quantum devices.
What the EIC Award Promised, and What the Record Shows
The award promised a hardware-agnostic platform combining quantum and high-performance computing for drug discovery. The record shows all three products launched, the last one four months after the project ended. The accounts do not report revenue; they show a gross loss, meaning external costs exceeded sales in both 2024 and 2025. Management describes the company's primary future income as product sales "supplemented with grants".
- Drug discovery softwareDeliveredTwo Koffee products, 2024.
- Quantum platformDeliveredQrunch, November 2025.
- Follow-on investmentDelivered€7M round, 2026.
- Commercial tractionNot yetGross loss in 2025.
The Money
Kvantify has lost DKK 92.5 million from 2022 to 2025. Its share premium reached DKK 72.7 million by the end of 2024. In 2025 it took on DKK 39.2 million of convertible and profit-sharing debt, which kept its cash at DKK 24.1 million even as equity turned negative. How much of the €7 million round came from the EIC Fund has not been disclosed.
What Cannot Be Checked
Questions for the EIC
How much the EIC Fund invested, how many paying customers Kvantify has, what its revenue is, and why a co-founder left the executive board are not public.
Why Europe Should Care
Quantum computing is a field where Europe wants its own champions, and the EIC Fund's chair said Kvantify's work "represents a transformative opportunity for Europe to lead". The EIC has backed the company twice, through the grant and through equity. Whether customers will pay for quantum chemistry before the hardware matures is still open.
What the award promised
The first user-friendly software platform coupling quantum and classical computing for drug discovery.
What the record shows
Three launched products, a new funding round, a gross loss and a smaller team.
The Verdict
Delivered ahead of its market
Kvantify built what the EIC paid for and attracted more EU money on the back of it. Paying demand has not yet followed.
Kvantify and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.
